Generic Name and Formulations:
Sodium hyaluronate 5000 23mg/mL; viscoelastic soln for intraocular use.
Indications for HEALON5:
Inject through a fine cannula into the eye. Amount varies depending on surgery, repeated inj may be required. One syringe of 0.6mL is usually sufficient in anterior segment surgery.
Single use only; reuse may cause inflammatory reaction. Glaucoma; consider prophylactic pressure-lowering treatment. Complete removal of soln necessary to avoid intraocular pressure peaks post-op.
Incompatibility, resulting in opalescence, between sodium hyaluronate and solutions containing quaternary ammonium ions (eg, detergents, benzalkonium chloride).
Ophthalmic viscosurgical device.
Transient rise in intraocular pressure, myopic shift (if product not completely removed).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma